Non-melanoma skin cancer: new and future synthetic drug treatments

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2017-04-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14656566.2017.1316372PMID 28414587
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Occurrence of malignancies after kidney transplantation in adults: Slovak multicenter experience.

  2017cited by this paper
• Updates on the Management of Non-Melanoma Skin Cancer (NMSC)

  2017cited by this paper
• Understanding the Molecular Genetics of Basal Cell Carcinoma

  2017cited by this paper
• Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer

  2017cited by this paper
• Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma

  2016cited by this paper
• Rescue therapy with anti‐programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases

  2016cited by this paper
• The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.

  2016cited by this paper
• Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.

  2016cited by this paper
• Efficacy and safety of sonidegib in patients (pts) with locally advanced (la) or metastatic (m) basal cell carcinoma (BCC): BOLT 30-month analysis.

  2016cited by this paper
• Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs).

  2016cited by this paper
• VISMONEO - a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma - Patients characteristics

  2016cited by this paper
• Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).

  2016cited by this paper
• Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.

  2016cited by this paper
• Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.

  2015cited by this paper
• Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.

  2015influential reference
• Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden, Germany

  2015cited by this paper
• The RegiSONIC disease registry: Preliminary effectiveness and safety in the first 66 newly diagnosed locally advanced basal cell carcinoma (BCC) patients treated with vismodegib.

  2015cited by this paper
• Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

  2015cited by this paper
• An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib

  2015cited by this paper
• Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma

  2015cited by this paper
• Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas

  2015cited by this paper
• Pharmacologic treatment options for advanced epithelial skin cancer

  2015cited by this paper
• Non-melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma

  2015cited by this paper
• Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.

  2015cited by this paper
• Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

  2015cited by this paper
• A phase II, single-armed, multicenter trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma: NICCI.

  2014cited by this paper
• An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma.

  2014cited by this paper
• Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma.

  2014cited by this paper
• Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma.

  2014cited by this paper
• Context-dependent signal integration by the GLI code: The oncogenic load, pathways, modifiers and implications for cancer therapy

  2014cited by this paper
• Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease.

  2014cited by this paper
• A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors

  2014cited by this paper
• A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors

  2014cited by this paper
• Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.

  2014cited by this paper
• Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.

  2014cited by this paper
• Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response.

  2013cited by this paper
• A meta-analysis of pigmentary characteristics, sun sensitivity, freckling and melanocytic nevi and risk of basal cell carcinoma of the skin.

  2013cited by this paper
• Risk factors for non-melanoma skin cancer in kidney transplant patients in a Spanish population in the Mediterranean region.

  2013cited by this paper
• Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.

  2013cited by this paper
• Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients.

  2013cited by this paper
• Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011.

  2013cited by this paper
• Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies

  2013cited by this paper
• Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

  2013cited by this paper
• A systematic review of worldwide incidence of nonmelanoma skin cancer

  2012cited by this paper
• Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.

  2012cited by this paper
• A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck

  2012cited by this paper
• Microdeletion 9q22.3 syndrome includes metopic craniosynostosis, hydrocephalus, macrosomia, and developmental delay

  2012cited by this paper
• Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.

  2012influential reference
• Dual function of suppressor of fused in Hh pathway activation and mouse spinal cord patterning.

  2012cited by this paper
• Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

  2012influential reference
• Hereditary nonmelanoma skin cancer.

  2012cited by this paper
• Limb anterior-posterior polarity integrates activator and repressor functions of GLI2 as well as GLI3.

  2012cited by this paper
• Radiation-related risk of basal cell carcinoma: a report from the Childhood Cancer Survivor Study.

  2012cited by this paper
• Boc and Gas1 each form distinct Shh receptor complexes with Ptch1 and are required for Shh-mediated cell proliferation.

  2011cited by this paper
• Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.

  2011cited by this paper
• Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

  2011cited by this paper
• Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy.

  2011cited by this paper
• Hereditary tumour syndromes featuring basal cell carcinomas

  2011cited by this paper
• The output of Hedgehog signaling is controlled by the dynamic association between Suppressor of Fused and the Gli proteins.

  2010cited by this paper
• Treatment of unresectable and metastatic cutaneous squamous cell carcinoma.

  2010cited by this paper
• Interventions for non-metastatic squamous cell carcinoma of the skin.

  2010cited by this paper
• Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.

  2009cited by this paper
• Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

  2009cited by this paper
• Basal Cell Skin Cancer after Total-Body Irradiation and Hematopoietic Cell Transplantation

  2009cited by this paper
• GDC-0449-a potent inhibitor of the hedgehog pathway.

  2009cited by this paper
• Cetuximab Therapy of Metastasizing Cutaneous Squamous Cell Carcinoma in a Patient with Severe Recessive Dystrophic Epidermolysis Bullosa

  2009cited by this paper
• Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation.

  2009cited by this paper
• Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

  2009cited by this paper
• Exposure profiles and human papillomavirus infection in skin cancer: an analysis of 25 genus beta-types in a population-based study.

  2008cited by this paper
• Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight.

  2008cited by this paper
• Basal cell carcinomas: attack of the hedgehog

  2008cited by this paper
• Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.

  2008cited by this paper
• Factors affecting the recurrence rate of basal cell carcinoma.

  2007cited by this paper
• Interventions for basal cell carcinoma of the skin.

  2007cited by this paper
• Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.

  2007cited by this paper
• Squamous Cell and Basal Cell Carcinoma of the Skin in Relation to Radiation Therapy and Potential Modification of Risk by Sun Exposure

  2007cited by this paper
• Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin.

  2006cited by this paper
• Orchestrating ontogenesis: variations on a theme by sonic hedgehog

  2006cited by this paper
• Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway.

  2006influential reference
• The Hedgehog Signaling Pathway in Cancer

  2006cited by this paper
• Comparison of risk patterns in carcinoma and melanoma of the skin in men: a multi-centre case–case–control study

  2006cited by this paper
• Metastatic Basal Cell Carcinoma: Complete Response to Chemotherapy and Associated Pure Red Cell Aplasia

  2006cited by this paper
• Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study.

  2005cited by this paper
• Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism

  2005cited by this paper
• Basal cell nevus syndrome

  2005cited by this paper
• Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.

  2005cited by this paper
• in a Population Younger Than 40 Years Incidence of Basal Cell and Squamous Cell Carcinomas

  2005cited by this paper
• Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial.

  2004cited by this paper
• Interventions for basal cell carcinoma of the skin: systematic review

  2004cited by this paper
• Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours

  2003cited by this paper
• Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

  2003cited by this paper
• Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis

  2003cited by this paper
• Interventions for basal cell carcinoma of the skin.

  2003cited by this paper
• Prognostic Factors for Metastasis in Squamous Cell Carcinoma of the Skin

  2002cited by this paper
• PTCH mutations in squamous cell carcinoma of the skin.

  2001cited by this paper
• Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.

  2001cited by this paper
• Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb.

  2000cited by this paper
• Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis.

  2000cited by this paper

• Is there an association of blood cadmium level with nonmelanoma skin cancer: results from a cross-sectional study

  2025cites this paper
• Towards Accurate Skin Cancer Screening: A CNN Model for Dermatological Images

  2025cites this paper
• Recent Research Trends Against Skin Carcinoma - An Overview.

  2024cites this paper
• Lagerstroemin from Lagerstroemia speciosa as Antibreast Cancer Candidate Targeting AURKA, EGFR and SRC Protein: A Comprehensive Computational Study

  2024cites this paper
• A European Consensus on the Consistent Use of the Term “Keratinocyte Cancer”

  2024cites this paper
• Orobol, 3'-hydroxy-genistein, suppresses the development and regrowth of cutaneous SCC.

  2023cites this paper
• The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis

  2023cites this paper
• Multimodal Analysis of Unbalanced Dermatological Data for Skin Cancer Recognition

  2023cites this paper
• Advancing Cancer Research: Current Knowledge on Cutaneous Neoplasia

  2023cites this paper
• Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years

  2022influential citation
• Pristimerin mediated anticancer effects and sensitization of human skin cancer cells through modulation of MAPK signaling pathways.

  2022cites this paper
• Wounding Therapies for Prevention of Photocarcinogenesis

  2022cites this paper
• Drug Resistance in Skin Diseases

  2021cites this paper
• Non-Melanoma Skin Cancer in People Living With HIV: From Epidemiology to Clinical Management

  2021cites this paper
• A BRIEF REVIEW OF TREATMENT MODALITIES FOR NON-MELANOMA SKIN CANCER

  2021cites this paper
• miR‐18a expression in basal cell carcinoma and regulatory mechanism on autophagy through mTOR pathway

  2020cites this paper
• Characterisation of resistance mechanisms developed by basal cell carcinoma cells in response to repeated cycles of Photodynamic Therapy

  2019cites this paper
• New perspectives in Merkel cell carcinoma

  2019cites this paper
• Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?

  2019cites this paper
• Nanocarrier systems and iontophoresis: complementary approaches for targeted cutaneous delivery of hydrophobic and hydrophilic drugs

  2018cites this paper
• A Brief Review of the Pathophysiology of Non-melanoma Skin Cancer and Applications of Interpenetrating and Semi-interpenetrating Polymer Networks in Its Treatment

  2018cites this paper
• Updates on the Management of Non-Melanoma Skin Cancer (NMSC)

  2017cites this paper
• Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma

  2017cites this paper
• Reply to ‘Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma’

  2017cites this paper
• Understanding the Molecular Genetics of Basal Cell Carcinoma

  2017cites this paper
• Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer

  2017cites this paper
• Association of blood cadmium level with nonmelanoma skin cancer: a cross-sectional study

  year unknowncites this paper